【摘要】 本研究的目的在于制备表皮生长因子受体干扰序列-白细胞介素24的融合蛋白(EGFRi-IL-24),并鉴定其抗肿瘤活性。利用pET-22b表达系统在大肠杆菌中表达重组融合蛋白EGFRi-IL-24,Ni-NTA亲和层析柱纯化表达产物。经检测表达的融合蛋白经纯化后纯度超过了90%,该融合蛋白对MCF-7细胞的体外抑制率最高达到72.1%。为进一步研究融合蛋白EGFRi-IL-24的生物学功能及临床应用奠定了基础。更多还原

【Abstract】 The aim of the study is to express and to purify fusion protein(EGFRi-IL-24,human Epidermal Growth Factor Receptor interference sequence-Interleukin-24),and to test its activity in vitro tumor cell profiling.Fusion protein(EGFRi-IL-24)was expressed in prokaryotic vector pET-22b,and Ni-NTA agarose column was used to purify the fusion protein.MTT method was used to determine anti-tumor activity of fusion protein.The purity of EGFRi-IL-24 fusion protein was more than 90%,and MTT test proved that anti-tumor activity of the fusion protein.EGFRi-IL-24 fusion protein has been successfully expressed and purified in prokaryotic vector and showed potential to apply in targeting therapy and clinical application for tumor.更多还原